Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis.

ABSTRACT:

SUBMITTER: Gordon M

PROVIDER: S-EPMC8987360 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis.

Gordon Morris M Sinopoulou Vassiliki V Akobeng Anthony K AK Pana Mirela M Gasiea Rehab R Moran Gordon William GW

The Cochrane database of systematic reviews 20220407

<h4>Background</h4>There are a limited number of treatment options for people with corticosteroid-refractory ulcerative colitis. Animal models of inflammatory bowel disease and uncontrolled studies in humans suggest that tacrolimus may be an effective treatment for ulcerative colitis.<h4>Objectives</h4>To evaluate the efficacy and safety of tacrolimus for induction of remission in people with corticosteroid-refractory ulcerative colitis.<h4>Search methods</h4>We searched the Cochrane Gut group s ...[more]

PMID: 35388476

Similar Datasets

Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.

Project description:BackgroundVedolizumab is an effective therapy for ulcerative colitis (UC), but costly and slow to work. New clinical responses occur after 30 weeks of therapy.AimsTo enable physicians, patients, and insurers to predict whether a patient with UC will respond to vedolizumab at an early time point after starting therapy.MethodsThe clinical study data request website provided the phase 3 clinical trial data for vedolizumab. Random forest models were trained on 70% and tested on 30% of the data to predict corticosteroid-free endoscopic remission at week 52. Models were constructed using baseline data, or data through week 6 of vedolizumab therapy from 491 subjects.ResultsThe AuROC for prediction of corticosteroid-free endoscopic remission at week 52 using baseline data was only 0.62 (95% CI: 0.53-0.72), but was 0.73 (95% CI: 0.65-0.82) when using data through week 6. A total of 47% of subjects were predicted to be remitters, and 59% of these subjects achieved corticosteroid-free endoscopic remission, in contrast to 21% of the predicted non-remitters. A week 6 prediction using FCP ≤234 μg/g was nearly as accurate.ConclusionsA machine learning algorithm using laboratory data through week 6 of vedolizumab therapy was able to accurately identify which UC patients would achieve corticosteroid-free endoscopic remission on vedolizumab at week 52. Application of this algorithm could have significant implications for clinical decisions on whom to continue on this costly medication when the benefits of the vedolizumab are not clinically apparent in the first 6 weeks of therapy.

| S-EPMC5814341 | biostudies-literature

Probiotics for induction of remission in ulcerative colitis.